Lumosa Therapeutics partners with Camargo Pharmaceutical Services for the development of its analgesic in the US

Taipei, Taiwan-based Lumosa Therapeutics Co., Ltd., a company focused on developing treatments for neurological and inflammatory disease, announced recently that it had engaged Cincinnati-headquartered Camargo Pharmaceutical Services for regulatory consulting and strategic development services for LT1001 (Naldebain®, dinalbuphine sebacate IM injection) in the US.

Read more

OBI Pharma signs agreement with Abzena for ADC linker technology

Cambridge, UK-headquartered drug development technology and services provider Abzena plc, has signed a licensing agreement and a master services and clinical supply agreement with Taipei, Taiwan biotech OBI Pharma (TPEx: 4174) for its novel site-specific ThioBridge™ antibody drug conjugate (ADC) linker technology to develop OBI’s proprietary ADC, OBI-999 and a series of further ADCs as potential treatments for cancer.

Read more

BioBusiness Asia 2017 examines global trends, new technologies shaping healthcare

BioBusiness Asia, the two-day business-themed life sciences conference held annually in Taipei, Taiwan, recently concluded. A part of the week-long BioTaiwan festival of life science-focused events, the conference this year had a wide range of session themes with a particular emphasis on emerging technologies such as precision medicine, next generation sequencing, artificial intelligence (AI), synthetic biology, cancer immunotherapy, and digital health.

Read more

AOP Orphan and PharmaEssentia announce latest clinical results for Ropeginterferon alfa-2b in Polycythemia Vera

AOP Orphan Pharmaceuticals AG of Vienna, Austria (AOP Orphan) and Taipei, Taiwan-headquartered PharmaEssentia Corporation (TPEx: 6446) together announced the latest results from three clinical studies on Ropeginterferon alfa-2b for patients with Polycythemia Vera (PV) presented at the 22nd Congress of the European Hematology Association (EHA) in Madrid, Spain.

Read more